NATURAL ANTIOXIDANTS AND NEURODEGENERATIVE DISEASES

S. Bastianetto and R. Quirion

Douglas Hospital Research Centre, Department of Psychiatry, McGill University, 6875 LaSalle Boulevard, Montreal, Québec, H4H 1R3 Canada

TABLE OF CONTENT

1. Abstract
2. Evidence of oxidative stress in pathological brain aging
3. Clinical efficacy of natural antioxidants
   3.1. Food and beverage
   3.2. Vitamins
   3.3. The ginkgo biloba extract EGB 761
   3.4. Acetyl-l-carnitine
   3.5. Alpha-lipoic acid
4. Proposed mechanisms of action underlying the neuroprotective effects of the natural antioxidants
5. Conclusion
6. Acknowledgements
7. References

1. ABSTRACT

Neurodegenerative diseases such as Alzheimer’s (AD) and Parkinson’s (PD) diseases are defined by a progressive neuronal dysfunction and an ensuing behavioral dysfunction. Although protein aggregation (i.e. beta-amyloid and alpha-synuclein) plays a pivotal role in both AD and PD, there is increasing evidence that excessive accumulation of reactive oxygen species (ROS) that occurs during normal and pathological brain aging contributes to neuronal losses and dysfunction. Based on these observations, it has been hypothesized that natural antioxidants derived from food, beverages and natural extracts may be beneficial to prevent or delay the occurrence of age-related cognitive deficits and neurodegenerative diseases. We will summarize in this review the role of oxidative stress in pathological brain aging, and provide evidence for a role for antioxidant molecules as therapeutic agents. We will also focus on the various mechanisms underlying their neuroprotective effects in in vivo and in vitro models of neurotoxicity.

2. EVIDENCE OF OXIDATIVE STRESS IN PATHOLOGICAL BRAIN AGING

Reactive oxygen species (ROS) are produced by different sources that include direct interactions between redox-active metals (i.e. copper, iron) and oxygen species, disruption of calcium homeostasis, and the release of hydrogen peroxide (H$_2$O$_2$) from mitochondria (for review, see 1). The excessive generation of ROS stimulates intracellular calcium signaling to elicit excitotoxicity, leading to further production of ROS and subsequent cell death (2). Age-related increase in transition metals (i.e. copper, iron, zinc) levels are also a major source of free-radical production in the brain and play a pivotal role in Parkinson’s (PD) and Alzheimer’s (AD) diseases (1). Disruption of the homeostasis of Zn, Cu and Fe occurs in AD brain and results in increased levels of beta-amyloid (Aβ) fragments that in turn cause ROS production, through an interaction with Cu, Zn and Fe. Moreover, studies have also reported a direct interaction of Fe with α-synuclein that results in the aggregation and formation of protein deposits similar to those seen in PD (3).

Post-mortem analyses of AD and PD brains have demonstrated evidence of oxidative stress including elevated levels of products of lipid peroxidation (e.g. 4-hydroxy-2,3-nonenal, malondialdehyde and thiobarbituric acid-reactive substances) and DNA alterations. PD is associated with a significant increase in Fe contents in regions (e.g. substantia nigra) severely affected by oxidative damage-associated neurodegeneration (4). Increased activity or levels of endogenous antioxidant enzymes (i.e. catalase, superoxide dismutase, glutathione peroxidase and glutathione reductase) have also been observed along with β-amyloid deposits in temporal regions (e.g. hippocampus) of the AD brain, reflecting a compensatory mechanism to counter oxidative stress (1).

3. CLINICAL EFFICACY OF NATURAL ANTIOXIDANTS

3.1. Food and beverage

Accumulating evidence suggests that fruits and vegetables intake decreases the risk of age-related neurological disorders (for review, see 5). These effects are likely due to the presence of polyphenols in foods. In support of this hypothesis, an epidemiological study performed in 5000 elderly subjects reported that fruit and vegetable-derived flavonoid intake (mean consumption = 14.4 mg/day) was inversely correlated with the risk of dementia, with a relative risk (RR) of 0.45 (6). In this study, the most important source was fruits (35%), followed by vegetables, wine and tea (from 16 to 19%) (6). Moreover, another study suggested that dietary antioxidant flavonoids (more than 28.6 mg/day) protect against stroke (RR = 0.27) in a cohort of 500 men aged 50 to 69 years (7).
results were confirmed by Johnsen et al (8) who demonstrated that persons in the top quintile of fruit and vegetable intake (median: 673 g/d) had a lower risk ratio of ischemic stroke (RR = 0.72) relative to persons in the bottom quintile (median: 147 g/d). The association appeared the most evident for fruit intake (RR = 0.60), particularly for citrus fruit (8). The beneficial effects of fruits were shown in another study reporting that the consumption of apples decreased the risk of thrombotic stroke both in men and women, with a relative risk of 0.60. This association seems not to be due only to the presence of the antioxidant flavonoid quercetin (9). Another 8 years follow-up study that enrolled persons aged 34 to 75 years reported that those in the highest quintile of fruit and vegetable intake (median of 5-6 servings per day) had a lower risk of stroke (RR = 0.69) compared with those in the lowest quintile, with cruciferous vegetables, green leafy vegetables and citrus fruit being the most effective (10).

Finally, a prospective 8 years cohort study performed with 40000 Japanese demonstrated that daily consumption of green-yellow vegetables and fruits is associated with a lower risk of total stroke, intracerebral hemorrhage, and cerebral infarction mortality, with a significant 25-35% reduction compared with an intake of once or less per week (11).

Recent reports suggested that daily consumption of 3-4 glasses of red wine may be linked to lower risks of AD, cognitive impairment and macular degeneration (AMD) (12-17). Wine appeared to be more effective than liquors and beer, (13, 17; but see 16), in particular in elderly individuals without the APOE epsilon-4 allele (17). Other studies reported that a moderate consumption of alcohol ameliorated cognitive performance (18) and was associated with reduced white matter changes (15), relative to elderly that do not consume alcohol.

Clinical evidence supporting a beneficial role for various kinds of tea is still rather limited. In a study performed by Keli et al (7), black tea was the major source (about 70%) of flavonoid intake found to diminish the risk of stroke. Regarding tea consumption, the relative risk of stroke for a daily consumption of 4.7 cups or more of tea per week (median: 673 g/d) had a lower risk ratio of 0.69 compared with those in the lowest quintile, with cruciferous vegetables, green leafy vegetables and citrus fruit being the most effective (10). It is likely that at least most of the purported beneficial effects of food (fruits, vegetables) and beverage (red wine, tea) relate to the presence of antioxidant polyphenols. Indeed, animal studies showed that polyphenols derived from fruits (e.g. blueberries) and vegetables (e.g. spinach) delayed and even reversed age-related cognitive behavioral impairments (21), whereas green tea (e.g. catechin derivatives) and red wine (e.g. catechin, resveratrol, quercetin) polyphenols have demonstrated neuroprotective activity in cell cultures and animal models (22-28).

3.2. Vitamins

The Rotterdam Study reported that dietary vitamins C and E lowered the risk of stroke in smokers (29). However, its was not confirmed by two cohort studies performed with male smokers, aged 50 to 69 years (30,31), whereas another report showed that α-tocopherol supplementation increased the risk of fatal hemorrhagic strokes but prevented cerebral infarction in hypertensive men (32,33). This discrepancy may be due to confounding factors and controlled clinical trials will be required to confirm the effectiveness of vitamins E and C supplementation in the prevention of stroke. Regarding other age-related neurological diseases, high dietary intake of vitamin E (10 mg per day) – but not vitamin C – dose-dependently decreased the risk of PD with an odd ratio of 0.5 (34). Moreover, daily intake of a combination of vitamins E and C supplements is associated with reduced prevalence and incidence of AD (35) while the consumption of vitamins E or C from supplements or diet failed to be protective (35,36). This discrepancy may be due to the type of individuals selected in a cohort. For example, another study performed by Morris et al (37) suggested that the protective effect of vitamin E intake from food against AD was observed only among individuals that did not carry the APOE e4 allele. Finally, two clinical trials suggested that a two-year treatment with α-tocopherol along with selegiline significantly reduced functional and cognitive deterioration in AD patients (38,39).

3.3. The ginkgo biloba extract EGb 761

The Ginkgo biloba extract referred as EGb 761 (IPSEN laboratories, France) is a standardized extract that is widely prescribed in Europe for the treatment of patients with AD, vascular dementia or age-associated memory impairment. A meta-analysis performed by the Cochrane Collaboration concluded that EGb 761 is effective to treat memory loss and cognitive impairment in demented patients, compared with placebo (40). The mechanisms of action of EGb 761 likely include a vasodilatory action as well as antioxidant properties of flavonoid components found in the total extract. In support of this hypothesis, we have reported that the flavonoid fraction may account, at least in part, for the protective effects of the total extract against toxicity induced by β-amyloid in hippocampal cells (41).

3.4. Acetyl-l-carnitine

Acetyl-l-carnitine (ALC) is an amino acid derived from carnitine that possesses several properties including antioxidant activities and enhancing mitochondrial function. A meta-analysis indicated that a 3- to 6-month treatment with ALC improves clinical global impression on AD patients, although it does not seem to show benefit on cognition or the severity of dementia (42,43). Clinical use of ALC remains controversial and further controlled clinical trials are now required in order to confirm its potential beneficial effects.

3.5. Alpha-lipoic acid

Alpha lipoic acid (ALA) is an endogenous antioxidant that interrupts cellular oxidative processes in both its oxidized and reduced forms (44). In the absence of randomized double-blind placebo-controlled trials, there is no evidence suggesting that ALA may be helpful in treating patients with dementia (45).
4. PROPOSED MECHANISMS OF ACTION UNDERLYING THE NEUROPROTECTIVE EFFECTS OF THE NATURAL ANTIOXIDANTS

Numerous in vitro and animal studies reported on the neuroprotective effects of natural antioxidants (i.e. vitamin E, EGB 761, alpha-lipoic acid, acetyl-l-carnitine, red wine- and green tea-derived polyphenols) in models of toxicity induced by oxidative stress or beta-amyloid (22-28,41,46-53). Other natural antioxidants such as curcumin, lycopene and beta-carotene have yet to be properly tested in clinical trials but are known to display protective effects in in vitro models of Aβ- or oxidative stress-induced toxicities (54,55). It is well established that the neuroprotective effects of these antioxidant compounds involve their radical scavenging and metal chelating activity and/or the regulation of antioxidant enzymes. Most interestingly, however, emerging evidence suggest that various intracellular signalling pathways, in addition to free radical scavenging properties, play a central role in the neuroprotection induced by natural products. These signalling molecules include the mitogen-activated protein (MAP) kinases, extracellular signal-regulated kinases 1 and 2 (ERK1/2), protein kinase C (various isoforms), phosphatidylinositol-3-kinase-Akt (PI3/Akt), and the transcription factor NF-κB (24,28,48,49,51,56-59). Moreover, molecular biology studies suggested that natural antioxidants were able to modulate the expression of genes that encode for apoptosis-related molecules such as caspases, p53, Bcl-2 or bax (26,60,61,62). Finally, it has been shown that some natural molecules/extracts such as EGB 761, curcumin or polyphenols inhibit the formation, extension, and destabilization of beta-amyloid fibrils, amyloid-beta aggregation or beta-amyloid-derived diffusible neurotoxic ligands (60,63-65).

5. CONCLUSION

Natural antioxidants appear to be promising molecules/extracts to prevent or delay the occurrence of neurodegenerative diseases. Although accumulating evidence on the health properties of natural antioxidants is associated with their well-known antioxidant properties, other mechanisms involving modulatory effects on signal transduction pathways and gene expression likely also play predominant roles. These multiple mechanisms of actions – that may be synergistic or additive – likely explain the variability of their clinical efficacy. To date, vitamin E and EGB 761 appear the most effective natural antioxidants in AD, while vitamin E failed to show significant benefit in reducing the incidence of stroke. Randomized controlled trials are now urgently needed to confirm or investigate the clinical efficacy of molecules such as acetyl-l-carnitine, alpha-lipoic acid and polyphenols (e.g. epigallocatechin gallate, resveratrol etc.) in various neurodegenerative diseases.

6. ACKNOWLEDGEMENTS

This work is supported by the Canadian Institutes of Health Research

7. REFERENCES


Natural antioxidants


Natural antioxidants


Natural antioxidants


**Key Words:** Vitamins, Polyphenols, Natural Extracts, Alzheimer, Stroke, Brain Aging, Review

**Send correspondence to:** Rémi Quirion, Ph.D., Douglas Hospital Research Centre, 6875 LaSalle Boulevard, Montréal, Québec, H4H 1R3 Canada, Tel. No.: 514-761-6131 ext. 2934, Fax No.: 514-762-3034, E-mail: remi.quirion@douglas.mcgill.ca